AI Article Synopsis
- BAFF is a B-cell growth factor whose serum levels were measured in 50 myeloma patients and compared with disease activity markers.
- Results indicated that patients had higher serum BAFF levels than controls, and levels decreased during the plateau phase of the disease.
- Higher BAFF levels were associated with shorter survival, implying it could serve as a prognostic marker and therapeutic target in myeloma treatment.
Article Abstract
B-cell activating factor (BAFF) is a B-cell growth factor. We measured its serum levels and correlated them with parameters of disease activity, as serum levels of tumor necrosis factor-α and lactate dehydrogenase, bone marrow microvascular density and proliferating cell nuclear antigen expression, in 50 myeloma patients, in 22 of them in plateau phase and in 20 controls. All of them were higher in patients and in advanced disease while reduced in plateau phase. BAFF correlated with all the above markers. Higher BAFF levels predicted a shorter survival, suggesting an important prognostic marker and a possible therapeutic target in myeloma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.leukres.2012.03.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!